GAIN2: Adjuvant phase III trial comparing an intensified dose-dense (idd) adjuvant therapy with EnPC compared to a dose-dense (dd), dose-adapted therapy with dtEC-dtD in patients with primary high risk breast cancer: Results of the second safety interim analysis

被引：0

作者：

Moebus, V. ^{[1
]}

Lueck, H. -J.

Forstbauer, H. ^{[2
]}

Wachsmann, G. ^{[3
]}

Ober, A. ^{[4
]}

Schneeweiss, A. ^{[5
]}

Christensen, B. ^{[6
]}

von Abel, E. ^{[7
]}

Grischke, E. -M. ^{[8
]}

Hoeffkes, H-G ^{[9
]}

Klare, P. ^{[10
]}

Ko, Y-D ^{[11
]}

Schmatloch, S. ^{[12
]}

Burchardi, N. ^{[13
]}

Loibl, S. ^{[13
]}

von Minckwitz, G. ^{[13
]}

机构：

[1] Klinikum Frankfurt Hochst GmbH, Frankfurt, Germany

[2] GOSPL, Troisdorf, Germany

[3] Frauenklin, Sindelfingen Boblingen, Germany

[4] St Vincenz Hosp, Limburg, Germany

[5] Univ Klinikum, Heidelberg, Germany

[6] Ruppiner Kliniken, Neuruppin, Germany

[7] Frauenklin, Schwabisch Gmund, Germany

[8] Univ Frauenklin, Tubingen, Germany

[9] Frauenklin, Fulda, Germany

[10] Praxisklin Brustzentrum, Berlin, Germany

[11] Johanniter Kliniken, Bonn, Germany

[12] Elisabeth Hosp, Kassel, Germany

[13] German Breast Grp, Neu Isenburg, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

0560

引用

页码：57 / 58

页数：2

共 50 条

[1] GAIN2: Adjuvant phase III trial comparing an intensified dose-dense adjuvant therapy with EnPC compared to a dose-dense, dose-adapted therapy with dtEC-dtD in patients with primary high risk breast cancer: Results of the second safety interim analysis
Moebus, V
Lueck, H. -J
Forstbauer, H.
Wachsmann, G.
Ober, A.
Schneeweiss, A.
Christensen, B.
Ekkehard, E.
Grischke, E. -M
Hoeffkes, H. -G
Klare, P.
Ko, Y. D.
Schmatloch, S.
Burchardi, N.
Loibl, S.
von Minckwitz, G.
Oncology Research and Treatment, 2015, 38 : 125 - 125
[2] Adjuvant phase III trial comparing an intensified dose-dense adjuvant therapy with EnPC compared to a dose-dense, dose-adapted therapy with dtEC-dtD in patients with primary high risk breast cancer
Noeding, S.
Forstbauer, H.
Wachsmann, G.
Ober, A.
Schneeweiss, A.
Christensen, B.
von Abel, E.
Grischke, E-M
Hoeffkes, H-G
Klare, P.
Ko, Y-D
Schmatloch, S.
Burchardi, N.
Loibl, S.
von Minckwitz, G.
Moebus, V
ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 111 - 112
[3] GAIN-2: Adjuvant phase III trial to compare intense dose-dense (idd) treatment with EnPC to tailored dose-dense (dt) therapy with dtEC-dtD for patients with high-risk early breast cancer: Results of the second safety interim analyses
Moebus, V.
Lueck, H-J
Forstbauer, H.
Wachsmann, G.
Ober, A.
Schneeweiss, A.
Christensen, B.
von Abel, E.
Grischke, E-M
Hoeffkes, H-G
Klare, P.
Yon-Dschun, K.
Schmatloch, S.
Furlanetto, J.
Burchardi, N.
Von Minckwitz, G.
Loibl, S.
CANCER RESEARCH, 2016, 76
[4] Adjuvant phase III trial to compare intense dose-dense adjuvant treatment with EnPC to dose dense, tailored therapy with dtEC-dtD for patients with high-risk early breast cancer (GAIN-2)
Moebus, Volker
Forstbauer, Helmut
Wachsmann, Grischa
Schneeweiss, Andreas
Ober, Angelika
von Abel, Ekkehard
Krabisch, Petra
Hoeffkes, Heinz-Gert
Kast, Karin
Christensen, Bernd
Niedermeier, Michael
Daryal, Mustafa
Uleer, Christoph
Fauster, Yvonne
Goehler, Thomas
Loibl, Sibylle
Nekljudova, Valentina
von Minckwitz, Gunter
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[5] Neo-/adjuvant phase III trial to compare intense dose-dense (idd) treatment with EnPC to tailored dose-dense (dt) therapy with dtEC-dtD for patients with high-risk early breast cancer: Results on pathological complete response (pCR) for patients treated within the neoadjuvant setting.
Moebus, Volker
Noeding, Stefanie
Ladda, Ekkehart
Klare, Peter
Schmidt, Marcus
Schneeweiss, Andreas
Janni, Wolfgang
Marme, Frederik
Reimer, Toralf
Schmatloch, Sabine
Stickeler, Elmar
Untch, Michael
Sinn, Bruno Valentin
Mueller, Volkmar
Fasching, Peter A.
Von Minckwitz, Gunter
Furlanetto, Jenny
Burchardi, Nicole
Loibl, Sibylle
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[6] Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2)
Moebus, Volker
Lueck, Hans-Joachim
Ladda, Ekkehart
Klare, Peter
Schmidt, Marcus
Schneeweiss, Andreas
Grischke, Eva-Maria
Wachsmann, Grischa
Forstbauer, Helmut
Untch, Michael
Marme, Frederik
Blohmer, Jens-Uwe
Jackisch, Christian
Huober, Jens
Stickeler, Elmar
Reinisch, Mattea
Link, Theresa
Sinn, Bruno, V
Janni, Wolfgang
Denkert, Carsten
Furlanetto, Jenny
Engels, Knut
Solbach, Christine
Schmatloch, Sabine
Rey, Julia
Burchardi, Nicole
Loibl, Sibylle
EUROPEAN JOURNAL OF CANCER, 2021, 156 : 138 - 148
[7] GAIN-2: Neo-/adjuvant phase III trial to compare intense dose dense chemotherapy (CT) to tailored dose-dense CT in patients (pts) with high risk early breast cancer (EBC): Results on safety and interim invasive disease-free survival (iDFS).
Moebus, Volker
Lueck, Hans-Joachim
Ladda, Ekkehart
Klare, Peter
Schmidt, Marcus
Schneeweiss, Andreas
Untch, Michael
Marme, Frederik
Huober, Jens Bodo
Stickeler, Elmar
Reinisch, Mattea
Link, Theresa
Sinn, Bruno Valentin
Furlanetto, Jenny
Reimer, Toralf
Solbach, Christine
Schmatloch, Sabine
Rey, Julia
Burchardi, Nicole
Loibl, Sibylle
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[8] Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial.
Foukakis, Theodoros
Papakonstantinou, Antroula
Matikas, Alexios
Bengtsson, Nils-Olof
Malmstrom, Per
Hedayati, Elham
Steger, Guenther G.
Untch, Michael
Hubbert, Laila
Johansson, Hemming
Hellstrom, Mats
Gnant, Michael
Loibl, Sibylle
Greil, Richard
Moebus, Volker
Bergh, Jonas C. S.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[9] Phase I/II feasibility trial of adjuvant dose-dense (DD) docetaxel/epirubicin/cyclophosphamide (TEC) in stage II/III breast cancer.
Burdette-Radoux, S
Wood, ME
Olin, JJ
Broom, R
Crocker, A
Ashikaga, T
Muss, HB
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 81S - 81S
[10] A randomised phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto)
Schneeweiss, Andreas
Moebus, Volker
Tesch, Hans
Hanusch, Claus
Denkert, Carsten
Luebbe, Kristina
Huober, Jens Bodo
Klare, Peter
Kummel, Sherko
Untch, Michael
Kast, Karin
Jackisch, Christian
Thomalla, Jorg
Heppner, Barbara Ingold
Blohmer, Jens U.
Rezai, Mandi
Frank, Matthias
Nekljudova, Valentina
Von Minckwitz, Gunter
Loibl, Sibylle
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

← 1 2 3 4 5 →